title: The role of antibody induction in liver transplantation.
abstract: Antilymphocyte antibody induction has been used in liver transplantation for decades, initially as part of a triple or quadruple immunosuppressive protocol to prevent rejection or in the treatment of steroid-resistant rejection. More recently there has been renewed interest in antibody induction in liver transplantation as part of a strategy to eliminate or reduce one or more immunosuppressive agents. This review highlights recent advances in the role of antibody induction in liver transplantation.
  
  
  
  Primary interest in antibody induction now falls into four major categories: steroid avoidance; calcineurin inhibitor reduction as a renal sparing protocol; minimal immunosuppression protocols (tolerance); and limiting hepatitis C recurrence. These protocols usually involve short courses of antibody induction in the peritransplant period, with decreased reliance on other agents after transplantation. Recent reports demonstrate several beneficial effects of antibody induction and suggest that, in the Model for End-Stage Liver Disease era, antibody induction in immunosuppressive strategies in liver transplantation will become increasingly important.
  
  
  
  Antibody induction in liver transplantation confers valuable benefit in limiting the adverse effects of maintenance immunosuppression. Antibodies allow the subsequent reduction or elimination of other agents to minimize overall immunosuppression.
authors.affiliation: Methodist University Transplant Institute, Memphis, Tennessee, USA.
authors.forename: James D
authors.initials: JD
authors.lastname: Eason
mesh_terms: D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D065095:Calcineurin Inhibitors; D006084:Graft Rejection; D006801:Humans; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016031:Liver Transplantation
chemical_list: D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents